Is Kezar Life Sciences, Inc. (KZR) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 31.8% / 30% | 260.2% / 30% | 1.8% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 31.8% / 33% | 260.2% / 33% | 1.8% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 11.2% / 33% | 91.4% / 33% | 0.6% / 33% | N/A | ✗ NOT HALAL |
| S&P | 31.8% / 33% | 260.2% / 33% | 1.8% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 11.2% / 33% | 91.4% / 33% | 0.6% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -59.9% | |
| Return on Assets (ROA) | -29.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$74M |
| Free Cash Flow | -$74M |
| Total Debt | $16M |
| Debt-to-Equity | 3.3 |
| Current Ratio | 11.5 |
| Total Assets | $145M |
Price & Trading
| Last Close | $6.35 |
| 50-Day MA | $6.51 |
| 200-Day MA | $5.38 |
| Avg Volume | 37K |
|
52-Week Range
$3.53
| |
About Kezar Life Sciences, Inc. (KZR)
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Kezar Life Sciences, Inc. (KZR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Kezar Life Sciences, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Kezar Life Sciences, Inc.'s debt ratio?
Kezar Life Sciences, Inc.'s debt ratio is 31.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 11.2%.
What are Kezar Life Sciences, Inc.'s key financial metrics?
Kezar Life Sciences, Inc. has a market capitalization of $45M. Return on equity stands at -59.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.